Navigation Links
Seamless gene correction of beta-thalassemia mutations in patient-specific cells
Date:8/5/2014

August 5, 2014 A major hurdle in gene therapy is the efficient integration of a corrected gene into a patient's genome without mutating off-target sites. In a paper published today in Genome Research, scientists have used CRISPR/Cas genome editing technology to seamlessly and efficiently correct disease-causing mutations in cells from patients with β-thalassemia.

β-thalassemia results from inherited DNA mutations in the hemoglobin beta (HBB) gene, resulting in reduced HBB expression in red blood cells and, in the most severe forms, anemia. The only established curative treatment is hematopoietic stem cell transplantation; however, this treatment requires a matched donor. Gene therapy, which delivers a corrected copy of a gene into patient cells, could bypass the need for a donor. Previous attempts using a virus to randomly insert a normal gene into the genome has been successful in one β-thalassemia patient, but the long-term effect of viral insertion is not yet known.

To correct HBB mutations directly in a patient's genome, researchers first generated induced pluripotent stem cells, or iPSCs, from skin cells of patients. The real breakthrough came when they applied CRISPR/Cas9 to precisely engineer a double strand DNA break at the HBB locus in these cells, allowing a donor plasmid with the corrected sites to be efficiently integrated, thus replacing the mutated sites. The donor plasmid also contained selectable markers to identify cells with corrected copies of the gene. These selectable markers were subsequently removed with transposase and a second round of selection, generating a seamless, corrected version of HBB in the patient's genome.

Importantly, the researchers could differentiate the corrected iPSCs into mature blood cells, and these blood cells showed restored expression of hemoglobin. However, much work is needed before these cells could be transplanted back into a patient for treating β-thalassemia. "Although we and others are able to differentiate iPSCs into blood cell progenitors as well as mature blood cells, the transplantation of the progenitors into mouse models to test them has so far proven very difficult," said senior author Yuet Wai Kan from the University of California, San Francisco. "I believe it will take quite a few more years before we can apply it in a clinical setting."


'/>"/>

Contact: Peggy Calicchia
calicchi@cshl.edu
516-422-4012
Cold Spring Harbor Laboratory
Source:Eurekalert  

Related biology technology :

1. Researchers advance scheme to design seamless integrated circuits etched on graphene
2. Rigaku publishes new WDXRF Application: Determination of Metals in Copper Concentrate by Advanced Correction Method for Fused Beads
3. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
5. deCODE genetics Uncovers Impact of Mutations in The Human Genome on Cognitive Ability
6. Annai Systems to Support International Challenge to Improve the Detection of Cancer Mutations
7. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
8. Spartan Bioscience Receives FDA Clearance for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs
9. Mutations in VCP gene implicated in a number of neurodegenerative diseases
10. Whole Genome Sequencing of Triple Negative Breast Cancer Reveals Previously Unreported Mutations
11. Autism mutations, scattered across many genes, merge into common network of interactions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Seamless gene correction of beta-thalassemia mutations in patient-specific cells
(Date:12/2/2016)... ANGELES , Dec. 2, 2016 CytRx ... and development company specializing in oncology, today announced the ... noted sarcoma surgeon, industry consultant, and private healthcare investor, ... is a healthcare leader with clinical and strategic experience ... , CytRx,s Chairman and CEO. "As one of the ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... the value of DNA microarray comparative genomic hybridization (array CGH) for HER2 ... Cancer Symposium. Using molecular test results from tumors with previously documented positive, ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced that the 3rd ... take place on February 1-3, 2017 at the Roosevelt Hotel in New York City. ... provides a unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, ...
(Date:12/2/2016)... Washington, DC (PRWEB) , ... ... ... Technologies Consortiumâ„¢ (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to ... is seeking companies interested in supplying a vendor-supported, portable online UHPLC, with ...
Breaking Biology Technology:
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):